Mineralys Therapeutics, Inc. financial data

Symbol
MLYS on Nasdaq
Location
150 N. Radnor Chester Road, Suite F200, Radnor, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.03K % +53.4%
Return On Equity -48.2 % +13.8%
Return On Assets -45.8 % +11.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79.1M shares +59%
Common Stock, Shares, Outstanding 79M shares +58.7%
Entity Public Float 400M USD +66.6%
Common Stock, Value, Issued 8K USD +60%
Weighted Average Number of Shares Outstanding, Basic 70.6M shares +41.7%
Weighted Average Number of Shares Outstanding, Diluted 70.6M shares +41.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 152M USD +3.03%
General and Administrative Expense 31.9M USD +54.6%
Operating Income (Loss) -184M USD -9.35%
Nonoperating Income (Expense) 12.7M USD -15.7%
Net Income (Loss) Attributable to Parent -171M USD -11.8%
Earnings Per Share, Basic -2 USD/shares +8.9%
Earnings Per Share, Diluted -2 USD/shares +8.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 218M USD +124%
Assets, Current 600M USD +124%
Property, Plant and Equipment, Net 7K USD -89.9%
Other Assets, Noncurrent 144K USD -68.1%
Assets 600M USD +124%
Accounts Payable, Current 1.12M USD -63.9%
Accrued Liabilities, Current 22.4M USD -20.6%
Liabilities, Current 23.5M USD -24.9%
Retained Earnings (Accumulated Deficit) -425M USD -67.6%
Stockholders' Equity Attributable to Parent 576M USD +143%
Liabilities and Equity 600M USD +124%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.5M USD -138%
Net Cash Provided by (Used in) Financing Activities 189M USD +62.9%
Net Cash Provided by (Used in) Investing Activities -92.9M USD -66%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 79M shares +58.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.9M USD +23.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 218M USD +124%
Deferred Tax Assets, Valuation Allowance 79.9M USD +154%
Deferred Tax Assets, Gross 79.9M USD +154%
Deferred Tax Assets, Operating Loss Carryforwards 15.6M USD +97.5%
Unrecognized Tax Benefits 4.51M USD +319%
Additional Paid in Capital 1B USD +104%
Depreciation, Depletion and Amortization 15K USD +87.5%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 17.2M USD +77.8%